Clinical trials of human papillomavirus vaccines and beyond
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.nature.com/articles/nrclinonc.2013.84.pdf
Reference111 articles.
1. International Agency for Research on Cancer. A Review of Human Carcinogens. Part B: Biological agents / IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 255–314 (Lyon, France, 2009).
2. Paavonen, J. et al. Efficacy of a prophylactic adjuvanted L1 VLP vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369, 2161–2170 (2007).
3. Lehtinen, M. et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13, 89–99 (2012).
4. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915–1927 (2007).
5. The FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341, c3493 (2010).
Cited by 142 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Glycan-induced structural activation softens the human papillomavirus capsid for entry through reduction of intercapsomere flexibility;2024-02-01
2. Scientific approaches toward improving cervical cancer elimination strategies;International Journal of Cancer;2024-01-09
3. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females;Vaccine;2023-10
4. Do Concurrent Multiple Infections with High-Risk HPVs Carry a More Malignant Potential than a Single Infection in the Uterine Cervix?;Journal of Clinical Medicine;2023-09-24
5. Molecular engineering tools for the development of vaccines against infectious diseases: current status and future directions;Expert Review of Vaccines;2023-06-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3